Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor ...
bdtonline.com
news
2022-10-20 11:03:41

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4Auvelity On My Side offers comprehensive patient support services including access and prescription drug support     NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AUVELITY™ (dextromethorphan HBr-bupropion HCl) is now available by prescription in the United States for the treatment of major depressive disorder (MDD) in adults.
